Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02469259 · ClinicalTrials.gov registry record · Early Phase 1

The Effects of Oxytocin on Startle Hyperreactivity in Patients With AUD and PTSD

A Early Phase 1 study of Stress Disorders, Post-Traumatic and Alcoholism, sponsored by University of California, San Francisco.

Completed
Registry status
Early Phase 1
Development phase
88
Enrollment target
1
Study location

NCT02469259: Completed Early Phase 1 study of Stress Disorders, Post-Traumatic and Alcoholism, sponsored by University of California, San Francisco.

NCT02469259 is a Early Phase 1 study of Stress Disorders, Post-Traumatic and Alcoholism that has completed, run by University of California, San Francisco. The registered enrollment target is 88 participants, below the 155-participant average among 66 other Stress Disorders, Post-Traumatic trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02469259, a Early Phase 1 study of Stress Disorders, Post-Traumatic and Alcoholism, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
Early Phase 1
Development phase
88 participants
Enrollment target
1
Study location

Study Summary

This study will investigate the effects of oxytocin on alcohol-related behaviors, social abilities, and physiological startle responses in healthy individuals and patients with posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) using a randomized, placebo-controlled, dose-tiered, between-subject study design. Specifically, the investigators will determine if intranasal administration of a single dose of the pro-social neuropeptide oxytocin decreases alcohol-related approach bias and cravings, enhances social abilities, and decreases physiological hyperactivity. The investigators will also determine the optimal dose to achieve these effects and will explore psychosocial predictors of responses to oxytocin. The proposed work has the potential to yield a novel pharmacological treatment for AUD and PTSD, both leading causes of disability in the US Military for which currently available treatments are inadequate.

Conditions Studied

Stress Disorders, Post-Traumatic Alcoholism

Interventions

  • OTHER Placebo
  • DRUG Oxytocin

Study Locations (1)

California

  • San Francisco Veterans Affairs Medical Center - San Francisco

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2016-02
Est. Completion 2018-02-28
Phase Early Phase 1
University of California, San Francisco

1,713 total trials

What the finished NCT02469259 record still lists

NCT02469259 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 155-participant average among 66 other Stress Disorders, Post-Traumatic trials with a reported enrollment target (43% lower).

The record links to 2 conditions, with Stress Disorders, Post-Traumatic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02469259 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT02469259 about?

NCT02469259 is a clinical study titled "The Effects of Oxytocin on Startle Hyperreactivity in Patients With AUD and PTSD". This study will investigate the effects of oxytocin on alcohol-related behaviors, social abilities, and physiological startle responses in healthy individuals and patients with posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) using a randomized, placebo-controlled, dose-tiered, be...

What is the current status of trial NCT02469259?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 88 participants. The study started on 2016-02. Estimated completion is 2018-02-28.

What conditions does trial NCT02469259 study?

This clinical trial studies the following conditions: Stress Disorders, Post-Traumatic, Alcoholism.

What interventions are being tested in trial NCT02469259?

The interventions under investigation include: Placebo (OTHER), Oxytocin (DRUG).

Who is sponsoring clinical trial NCT02469259?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02469259 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stress Disorders, Post-Traumatic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02469259's enrollment target sits among peer trials

88 33rd of 66 higher than 34 of 66 other Stress Disorders, Post-Traumatic trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stress Disorders, Post-Traumatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03843463 · 88 participants · Phase 2

    Escitalopram and Language Intervention for Subacute Aphasia

  • NCT04066348 · 88 participants · Phase 2

    TNF-α Treatment of Blast-Induced Tinnitus

  • NCT04331704 · 88 participants · Phase 4

    ANCHORS Alcohol & Sexual Health Study: UH3 Project

  • NCT04536103 · 88 participants

    Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02469259, the US trial registry maintained by the National Library of Medicine. NCT02469259 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.